Thomas Powles, Begoña P Valderrama, Shilpa Gupta, Jens Bedke, Eiji Kikuchi, Jean Hoffman-Censits, Gopa Iyer, Christof Vulsteke, Se Hoon Park, Sang Joon Shin, Daniel Castellano, Giuseppe Fornarini, Jian-Ri Li, Mahmut Gümüş, Nataliya Mar, Yohann Loriot, Aude Fléchon, Ignacio Duran, Alexandra Drakaki, Sujata Narayanan, Xuesong Yu, Seema Gorla, Blanca Homet Moreno, Michiel S van der Heijden
BACKGROUND: No treatment has surpassed platinum-based chemotherapy in improving overall survival in patients with previously untreated locally advanced or metastatic urothelial carcinoma. METHODS: We conducted a phase 3, global, open-label, randomized trial to compare the efficacy and safety of enfortumab vedotin and pembrolizumab with the efficacy and safety of platinum-based chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma...
March 7, 2024: New England Journal of Medicine